Personalis Expands Tempus Partnership to Enhance Cancer Diagnostics and MRD Testing Access

Expansion of Collaboration to Enhance Cancer Diagnostics

Personalis, Inc. and Tempus AI, Inc. are expanding their commercial partnership, originally established in November 2023, to enhance the availability of ultra-sensitive minimal residual disease (MRD) testing. This strategic collaboration positions Tempus as the exclusive commercial diagnostic partner for Personalis' NeXT Personal® Dx product. The partnership targets broad patient access for critical cancers, particularly breast and lung cancers, and aims to improve immunotherapy monitoring across all solid tumors. This expansion reflects a positive reception in the diagnostic market and signifies a commitment to advancing personalized cancer care.

The collaboration now extends its reach into the biopharma industry, enabling Tempus to offer Personalis' NeXT Personal® testing to pharmaceutical and biotech companies. This bundling strategy allows these entities to integrate MRD testing with other Tempus services in their clinical studies. Chris Hall, CEO of Personalis, expresses optimism that this partnership will not only enhance their market penetration but also create new opportunities within the biopharmaceutical sector. By combining their strengths, the companies aim to provide a comprehensive suite of solutions that addresses the evolving needs of cancer management.

As both companies prepare to present their collaborative efforts at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, they remain aware of the risks and uncertainties present in the healthcare market. Nevertheless, Personalis and Tempus are committed to fostering innovation and collaboration to improve cancer diagnostics and management. Their combined expertise in genomic profiling and personalized testing is set to pave the way for better patient outcomes in cancer treatment.

In addition to this partnership expansion, Personalis continues to focus on its core mission of transforming cancer management through personalized testing. The company's innovative approach leverages proprietary algorithms to offer insights into tumor and normal profiling, facilitating early detection of MRD and potential cancer recurrence. By enhancing their diagnostic capabilities, Personalis reinforces its position as a leader in the field of precision oncology.

As the landscape of cancer diagnostics evolves, collaborations such as the one between Personalis and Tempus highlight the importance of combining resources and expertise to deliver advanced solutions. The commitment to improving patient access to vital diagnostic tools underscores the companies' dedication to enhancing cancer care and ultimately improving patient outcomes in this challenging field.